Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Chow

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|May 1, 2025
Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response AnalysesTimothy Chow, Marek Wardecki, Michael Storek, et al.
Pediatric Research|February 11, 2019
Postnatal outcomes in lambs exposed antenatally and acutely postnatally to fluoxetineTuan Anh Nguyen, Timothy Chow, Wayne Riggs, et al.
Blood|December 12, 2023
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b studyShirley D'Sa, Josephine M I Vos, Wilma Barcellini, et al.
American Journal of Preventive Cardiology|February 3, 2026
Reproductive risk factors and prevalence of cardiovascular-kidney-metabolic syndrome among young womenTheresa Boyer, Allison W Peng, Michael Fang, et al.
Clinical and Translational Science|January 20, 2023
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitorTimothy Chow, Pirouz Shamszad, Christopher Vinnard, et al.
The Journal of Allergy and Clinical Immunology|August 31, 2023
United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactionsDavid A Khan, Elizabeth J Phillips, John J Accarino, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|May 1, 2025
Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response AnalysesTimothy Chow, Marek Wardecki, Michael Storek, et al.
Pediatric Research|February 11, 2019
Postnatal outcomes in lambs exposed antenatally and acutely postnatally to fluoxetineTuan Anh Nguyen, Timothy Chow, Wayne Riggs, et al.
Blood|December 12, 2023
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b studyShirley D'Sa, Josephine M I Vos, Wilma Barcellini, et al.
American Journal of Preventive Cardiology|February 3, 2026
Reproductive risk factors and prevalence of cardiovascular-kidney-metabolic syndrome among young womenTheresa Boyer, Allison W Peng, Michael Fang, et al.
Clinical and Translational Science|January 20, 2023
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitorTimothy Chow, Pirouz Shamszad, Christopher Vinnard, et al.
The Journal of Allergy and Clinical Immunology|August 31, 2023
United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactionsDavid A Khan, Elizabeth J Phillips, John J Accarino, et al.
Pageof 1